Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (21-30 of 205) with videos related to

Pageof 21
Sort By:
Current Hematologic Malignancy Reports|March 31, 2011
Predicting the response of CML patients to tyrosine kinase inhibitor therapyDeborah L White, Timothy P Hughes
Critical Reviews in Oncogenesis|April 5, 2012
Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemiaDavid T Yeung, Timothy P Hughes
Leukemia & Lymphoma|October 27, 2006
Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: back to the benchChi-Hung Hui, Timothy P Hughes
Nature Reviews. Clinical Oncology|May 8, 2020
Treatment-free remission in patients with chronic myeloid leukaemiaDavid M Ross, Timothy P Hughes
Blood|July 4, 2015
Living with CML: is death no longer the end (point)?Deborah L White, Timothy P Hughes
Current Hematologic Malignancy Reports|April 29, 2010
Predicting the response of CML patients to tyrosine kinase inhibitor therapyDeborah L White, Timothy P Hughes
British Journal of Haematology|April 24, 2014
How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemiaDavid M Ross, Timothy P Hughes
The New England Journal of Medicine|April 4, 2020
Asciminib in Relapsed Chronic Myeloid Leukemia. ReplyMichael J Mauro, Timothy P Hughes
British Journal of Haematology|June 13, 2002
Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR geneSusan Branford, Timothy P Hughes, Zbigniew Rudzki
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 24, 2025
Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia?Naranie Shanmuganathan, Michael Osborn, Timothy P Hughes
Pageof 21

Showing results (21-30 of 205) with videos related to

Sort By:
Pageof 21
Current Hematologic Malignancy Reports|March 31, 2011
Predicting the response of CML patients to tyrosine kinase inhibitor therapyDeborah L White, Timothy P Hughes
Critical Reviews in Oncogenesis|April 5, 2012
Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemiaDavid T Yeung, Timothy P Hughes
Leukemia & Lymphoma|October 27, 2006
Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: back to the benchChi-Hung Hui, Timothy P Hughes
Nature Reviews. Clinical Oncology|May 8, 2020
Treatment-free remission in patients with chronic myeloid leukaemiaDavid M Ross, Timothy P Hughes
Blood|July 4, 2015
Living with CML: is death no longer the end (point)?Deborah L White, Timothy P Hughes
Current Hematologic Malignancy Reports|April 29, 2010
Predicting the response of CML patients to tyrosine kinase inhibitor therapyDeborah L White, Timothy P Hughes
British Journal of Haematology|April 24, 2014
How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemiaDavid M Ross, Timothy P Hughes
The New England Journal of Medicine|April 4, 2020
Asciminib in Relapsed Chronic Myeloid Leukemia. ReplyMichael J Mauro, Timothy P Hughes
British Journal of Haematology|June 13, 2002
Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR geneSusan Branford, Timothy P Hughes, Zbigniew Rudzki
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 24, 2025
Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia?Naranie Shanmuganathan, Michael Osborn, Timothy P Hughes
Pageof 21